enVVeno Medical Corporation (NVNO)
$7.40-7.15%Close
SELLCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $122,122
- Beta
- 1.07
- P/E (TTM)
- -0.01
- Short % float
- 110.92%
- Days to cover
- 1.0
- SI change
- +44.1%
- 1W
- -11.90%
- 1M
- -20.60%
- vs SPY 1W
- -11.77%
- vs SPY 1M
- -23.11%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 10
- VALUE
- 12
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-37.4%
REV YoY-
ROE-62.3%
EPS YoY-
ROA-69.4%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.01
P/E FWD-
SECTOR PE20.48
INDUSTRY PE22.31
P/B0.24
P/FCF-
EV/EBITDA-0.18
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E2.44
ALTMAN Z-
CURR RATIO11.70
ND/EBITDA-
BETA1.07
Company news
FAQ
- What is LOPJLB’s current signal on NVNO?
- LOPJLB’s latest quantitative signal on enVVeno Medical Corporation (NVNO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is NVNO in?
- enVVeno Medical Corporation (NVNO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does enVVeno Medical Corporation (NVNO) do?
- enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoV…